Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Current Assets (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Current Assets over the past 3 years, most recently at $228.9 million for Q4 2025.

  • Quarterly results put Current Assets at $228.9 million for Q4 2025, up 92.33% from a year ago — trailing twelve months through Dec 2025 was $228.9 million (up 92.33% YoY), and the annual figure for FY2025 was $228.9 million, up 92.33%.
  • Current Assets for Q4 2025 was $228.9 million at Tonix Pharmaceuticals Holding, up from $208.1 million in the prior quarter.
  • Over the last five years, Current Assets for TNXP hit a ceiling of $228.9 million in Q4 2025 and a floor of $25.3 million in Q2 2024.
  • Median Current Assets over the past 3 years was $67.5 million (2023), compared with a mean of $97.4 million.
  • Biggest five-year swings in Current Assets: tumbled 64.05% in 2024 and later soared 467.62% in 2025.
  • Tonix Pharmaceuticals Holding's Current Assets stood at $47.8 million in 2023, then surged by 149.12% to $119.0 million in 2024, then surged by 92.33% to $228.9 million in 2025.
  • The last three reported values for Current Assets were $228.9 million (Q4 2025), $208.1 million (Q3 2025), and $143.5 million (Q2 2025) per Business Quant data.